IO Biotech CFO Amy Sullivan buys $8,482 in frequent inventory

COPENHAGEN—In a latest transaction, Amy Sullivan, the Chief Monetary Officer of IO Biotech, Inc. (NASDAQ:IOBT), bought 10,250 shares of the corporate’s frequent inventory. The shares have been acquired on December 23, 2024, at a weighted common value of $0.8276 per share, amounting to a complete transaction worth of $8,482. The acquisition comes because the inventory, presently buying and selling at $0.89, has proven robust momentum with a 13% achieve over the previous week. In accordance with InvestingPro evaluation, the corporate seems pretty valued at present ranges.

The acquisition was executed in a number of trades with costs starting from $0.7861 to $0.90 per share. Following this acquisition, Sullivan’s direct possession in IO Biotech elevated to 84,632 shares.

This transaction was disclosed in a submitting with the U.S. Securities and Change Fee.

In different latest information, IO Biotech has secured a mortgage facility of as much as €57.5 million from the European Funding Financial institution (EIB) to advance its therapeutic most cancers vaccines, together with IO102-IO103, which is anticipated to succeed in a Biologics License Software submission in 2025. The corporate anticipates the funding to increase its monetary runway into the second quarter of 2026. In different developments, IO Biotech has reported promising outcomes from a Section 2 trial of its lead investigational candidate, IO102-IO103, in treating sufferers with metastatic non-small cell lung most cancers. Furthermore, the corporate has enacted modifications to its company governance paperwork and financial calendar, in line with a latest SEC submitting. Analyst companies Piper Sandler and Morgan Stanley (NYSE:MS) have maintained an Chubby score on IO Biotech, whereas Jefferies and H.C. Wainwright saved their Purchase rankings. These rankings have been influenced by latest knowledge from the European Society for Medical (TASE:PMCN) Oncology convention and summary knowledge for IO Biotech’s IO102-103. Regardless of the corporate’s Section 3 trial not assembly the interim evaluation goal response price, the Unbiased (LON:IOG) Knowledge Monitoring Committee advisable the continuation of the research. Kathleen Sereda Glaub, Peter Hirth, and Mai-Britt Zocca have been elected as class III administrators, serving till the 2027 Annual Assembly of Stockholders. These are the latest developments for IO Biotech.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.